$2.31
+0.13(5.71%)
Mkt Cap $165M
$1.51
$2.73
52-Week Range
At a Glance
AI-generatedNkarta, Inc., a clinical-stage biopharmaceutical company developing allogeneic NK cell therapies for autoimmune diseases, reported a net loss of $104.1 million for FY 2025, an improvement from $108.8 million in FY 2024, driven by reduced research and development expenses of $90.4 million (down from $96.7 million) and lower general and administrative expenses, partially offset by higher other operating costs.
$165M
Market Cap
—
Revenue
-$98M
Net Income
Employees157
Fundamentals
How The Business Makes Money
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Industry Biotechnology
Activity
What Changed Recently
No significant events in the past 90 days.
Analyst View
Company Profile
CIK0001787400
ISINUS65487U1088
CUSIP65487U108
Phone415 582 4923
Address6000 Shoreline Court, South San Francisco, CA, 94080, US
SEC EDGAR